Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing will support the Phase 2 Alpestria-1 study and further profiling of EYP001 (vonafexor), a highly selective NR1H4 agonist, in other kidney diseases, such as Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Lead Product(s): Vonafexor
Therapeutic Area: Genetic Disease Product Name: EYP001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: OrbiMed
Deal Size: $42.5 million Upfront Cash: Undisclosed
Deal Type: Series C Financing January 03, 2024